RE:RE:RE:Newsletter out By including the 1st 12 undertreated patients, the numbers look less attractive, but only once we can have data on 15-20 patients who correctly treated with optimized procedure, then we will have a clear picture. So far we can say 8 patients ( 2 from PH1 and 6 from PH2) have received an optimized treatment. 4 out of 5 valuable patients are CR and 3 pending. That is 80% CR so far on valuable patients. Looking very good but need more data.IMO
enriquesuave wrote:
Yes that's the important part. Patients 13-18 or the last 6 patients have all been treated with optimized procedure. Of 13,14,& 15 2 are CR or 2 out of 3 after single treatment or 67%. Still waiting on 90 days for 16,17 & 18. We need to significantly beat the competition which is 17-24% CR efficacy at 12 months to become next Gold Standard as we already beat the competition for safety,and patient friendliness ( 2 Vs many more treatment instillations), as well as less hospital time. IMO looking good, by next report we should know on remaining patients and hopefully have more treated ( up to 7 more in Q2 or by end of June)
Oilminerdeluxe wrote: If i read it correctly, the 6 treated with the right dosage:
Although very early for a statistical analysis the primary objective at 90 days for patients receiving the optimized primary Study Treatment demonstrates a 33.3% CR rate, with 50.0% data pending and only 16.7% with no response.